Skip to main content
Premium Trial:

Request an Annual Quote

VistaGen Licenses Stem Cell Patents for Predictive Assays from WARF

NEW YORK (GenomeWeb News) — Stem cell technology company VistaGen Therapeutics and the Wisconsin Alumni Research Foundation have signed an agreement for patents to technology developed at the University of Wisconsin – Madison that may be used as predictive drug screening assays.
 
South San Francisco-based VistaGen plans to use the technology to speed up development of customized, next-generation stem cell-based predictive toxicology and drug screening assays.
 
Financial terms of the agreement were not released.
 

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.